Generic Oncology Drugs Market Scope And Analysis

  • Report Code : TIPRE00006393
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Generic Oncology Drugs Market Scope, Analysis, and Trends by 2031

Buy Now

Generic Oncology Drugs Market Report Generic Oncology Drugs Market Size and Share Generic Oncology Drugs Market Scope and Analysis

Generic Oncology Drugs Market Report Scope

Report Attribute Details
Market size in 2022 US$ 24.78 Billion
Market Size by 2031 US$ 42.43 Billion
Global CAGR (2023 - 2031) 6.3%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Molecular Type
  • Large Molecule
  • Small Molecule
By Indication
  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Kidney Cancer
  • Cervical Cancer
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Teva Pharmaceutical Industries LTD
  • Sandoz International GMBH
  • Glenmark Pharmaceuticals LIMITED
  • Sun Pharmaceutical Industries LTD
  • MSN Laboratories
  • Aurobindo Pharma
  • Intas Pharmaceuticals LTD
  • Zydus Cadila
  • Mylan N V
  • Shilpa Medicare LTD

    • Generic Oncology Drugs Market News and Recent Developments

    The Generic Oncology Drugs Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for neuro-interventional devices and strategies:

    • Zydus Lifesciences launched olaparib, a PARP inhibitor, under the brand name IBYRA in India, making advanced cancer treatment accessible to all. PARP (poly-ADP ribose polymerase) is a protein that helps damaged cells to repair themselves. As a cancer treatment, PARP inhibitors block the PARP from doing its repair work in cancer cells and the cell dies. (Source: Economic Times, Press Release, 2024)
    • Gland Pharma launched the cancer treatment drug Bortezomib for Injection in the US market. The company has launched the product in the US market through its partner which received approval from the US Food & Drug Administration. (Source: Economic Times, Press Release, 2022)

    Generic Oncology Drugs Market Report Coverage and Deliverables

    The “Generic Oncology Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles